NCT06391190View on ClinicalTrials.gov

Concurrent Chemoradiotherapy Followed by PD-1 Inhibitor in Advanced Cervical Cancer

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

January 1, 2022

Primary Completion Date

December 30, 2024

Study Completion Date

December 30, 2026

Conditions
Locally Advanced Cervical CarcinomaConcurrent ChemoradiotherapyImmunotherapy
Interventions
DRUG

Albumin-Bound Paclitaxel, cisplatin, Sintilimab

with Albumin-Bound Paclitaxel 50-75mg/m2, cisplatin 25-40 mg/m2 weekly for up to 5 cycles during radical radiation; followed by Sintilimab 200mg Q3W for 8 cycles

Trial Locations (1)

200127

RECRUITING

RenJi hospital, Shanghai

All Listed Sponsors
lead

RenJi Hospital

OTHER